Japan Ups Generic Use Target
This article was originally published in The Pink Sheet Daily
Japan's government has released a new "road map" for the development of the generic drug sector, setting an ambitious new five-year target for such products to reflect faster than expected sales expansion following recent policy changes.
You may also be interested in...
Industry groups in Japan have reacted swiftly and strongly to planned government discussions on changes to drug pricing policies, warning that the adoption of annual price cuts would "undo all the policy achievements" of the past few years.
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.